AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, announced $18M in Australian Federal Government Funding from the Medical Research Future Fund (MRFF) Frontiers Initiative for ‘Defeating Prostate...
Exicure, Inc. today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that...
serious adverse outcomes in pregnant women with APS and their babies. The study results were published online on April 10, 2025 in Annals of the Rheumatic Diseases. “The IMPACT study represents a bold and very successful partnership over many years...
positioned to continue its growth in the Asia Pacific region, where demand for clinical trials is forecasted to grow at 15% a year, in addition to focused expansion in the US and Europe. “Novotech is already on its way to be a major global player...
Pykus Therapeutics, Inc. ("Pykus" or the "Company") announced that it has completed enrollment of its pilot study (PYK-2101-RD001) in Australia. The study is evaluating the use of Pykus' proprietary, lead product candidate, PYK-2101, a focal...
IFF Pharma Solutions, a global leader in polymer innovations, announced the launch of Low Nitrite METHOCEL™ hydroxypropyl methylcellulose (HPMC), a range of low nitrite cellulose ethers developed to reduce the risk of nitrosamine formation in...
that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for "A Phase 1a/b Trial in Relapsed/Refractory Small Cell Lung Cancer (SCLC) to Determine the Safety Profile, Pharmacology, and Maximum...
smart in-app integrations to enhance its usability and impact. Key features include: Compact, Intuitive Design: With up to 14 spacious yet travel-friendly compartments and built-in light indicators, Pill Box seamlessly fits into daily routines at...
Clinical Trials: Emerald Clinical Trials is a leading clinical research organization operating worldwide that serves over 100 biotechs, and 6 of the top 10 pharmaceutical companies. Headquartered in Singapore and driven by operational expertise and...
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25...
Initiative (ADNI), Spectris patients maintained brain volume (+0.58%) while matched ADNI controls showed a decline (-0.91%), a net difference of +1.49% (p
chemically synthesized and animal component-free, enabling xeno-free and chemically defined cell culture media. PG-012, KGF alternative peptide, is a dimeric peptide composed of cyclic peptides designed to bind specifically to FGFR2b. Like KGF,...
active ingredients into a single capsule. Laboratorios Silanes, a leading pharmaceutical company in Mexico founded in 1943, is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established...
support models that grow with your business—ensuring the right expertise, at the right time. About Truliant: Founded in 2021 and headquartered in Baltimore, Maryland, Truliant Consulting is a women-owned business specializing in pharmacovigilance...
and management to health systems in the U.S. and U.K., announced it has been named by Fast Company as one of the World's 10 Most Innovative Companies in the medical device category. Profiled in the publication's March 18 feature, Bruin Biometrics...
Headquartered in Northfield, Illinois, the company employs more than 43,000 people worldwide and operates in more than 100 countries and territories. For more information please visit www.medline.com.
can progress to secondary myelofibrosis or leukemia. The global incidence of PV is estimated at approximately 2.8 cases per 100,000 people per year. In Brazil, between 2016 and 2020, DataSUS recorded 1,843 cases of Polycythemia Vera, representing...
medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac progenitor cell (nCPC) therapy, for the treatment of Heart Failure with Preserved Ejection Fraction...
President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic...
Company’s common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open today, Wednesday, March 19, 2025. The CUSIP number for the Company's common stock will remain the same. With a legacy spanning over 25 years, this...
